Galecto, Inc

Galecto, Inc. is a clinical-stage biotechnology company located in Boston, MA, at the forefront of developing innovative medicines for cancer and severe liver diseases. Founded by prominent scientists and biotech experts, Galecto has dedicated nearly 15 years to researching galectin modulators, with a focus on creating treatments that can work synergistically with existing therapies.

Through pioneering research, Galecto has identified galectin-3 and ENL-YEATS / FLT3 as crucial players in diseases like acute myeloid leukemia, melanoma, and hepatocellular carcinoma. Their groundbreaking work in fibrosis and cancer progression has led to the development of novel small molecules, including the dual ENL-YEATS / FLT3 inhibitor BRM-1420, offering hope for patients in multiple genetic subsets of AML.

By targeting central disease pathways and prioritizing patient well-being, Galecto aims to enhance the quality of life for individuals battling severe illnesses. Their mission is to provide highly effective and easily administered treatments that not only extend lifespan but also significantly improve overall health and comfort.

Generated from the website content